This was the stock's third consecutive day of gains.
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Hosted on MSN12d
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?Zoetis, Inc. ZTS is expected to beat estimates when it reports its fourth-quarter 2024 results on Feb. 13, before the opening ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Shares of Zoetis ( ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback